AcelRx Q2 net income $70.7M on $84.1M debt gain; revenue $0.6M

TALPHERA, INC.

2022-Q2 EPS reported $0.42 revenue$1,012,000

Net income of $70.7M ($0.48 diluted EPS) vs net loss of $9.9M in Q2 2021, driven by $84.1M gain on extinguishment of royalty monetization liability.
Revenue $0.6M; commercial ex-DoD unit sales up 133% YoY; total DSUVIA units 10,600.
Realigned cost structure reducing headcount ~40%, generating expected annual savings of $9M.
Cash and short-term investments $27.9M as of June 30, 2022; 983 DSUVIA formulary approvals achieved.
Niyad supply chain progress; targeting Emergency Use Authorization in 2023; DZUVEO EU launch on track for Q3.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.